3.4.11.3	diagnostics	the increase in serum IRAP activity can be an indicator of a misregulation of vasopressin (AVP) function	753943	
3.4.11.3	medicine	activities of soluble cystyl aminopeptidase do not differ between diabetic and control rats in both hippocampus and hypothalamus. Membrane-bound cystyl aminopeptidase is about 2.5foldincreased in the hypothalamus and 5fold increased in the hippocampus	682252	
3.4.11.3	medicine	blocking of alpha-1adrenoceptor by doxazosin increases enzyme activity in male, but not in female thalamus. Increased capacity of males to degrade vasopressin and to regulate cardiovascular homeostasis	683515	
3.4.11.3	medicine	development of stable second generation inhibitors of IRAP based on the AT4 ligands angiotensin IV or LVV-H7 may provide the opportunity for the development of therapeutics for memory loss in patients Altheimer's disease	667888	
3.4.11.3	medicine	enzyme isoform IRAP is involved in increasing malignant potential of endometrial cancer mediated by insulin. Endometrial adenocarcinoma A-MEC cells expressing the enzyme exhibit a significant growth-stimulatory effect compared with control. They have a remarkably high level of p85PI3K protein and show a higher degree of AKT phosphorylation by insulin stimulation	683302	
3.4.11.3	medicine	excessive activity of vasopressinase is probably responsible for gestational diabetes insipidus	699736	
3.4.11.3	medicine	marked decrease of membrane-bound cystinyl aminopeptidase activity in clear cell renal carcinoma cell, papillary renal carcinoma cell, and chromophobe renal carcinoma cell compared to surrounding non-tumor tissue. Minor and non-significant changes of enzyme activity in soluble fractions of carcinoma cells	684051	
3.4.11.3	medicine	Otsuka Long Evans Tokushima Fatty rats, model of type II Diabetes mellitus, show significantly lower cell surface IRAP equilibrium activity than control. Time to reach equilibrium is significantly longer and adipocytes isolated from the model rats demonstrate both a delay and a reduction in 3-O-methyl-D-glucose uptake	683907	
3.4.11.3	medicine	P-LAP is an independent prognosticator of clinical outcome in patients with endometrial carcinoma. Assessment of the P-LAP status provides clinically useful prognostic information in patients with endometrial carcinoma	670450	
3.4.11.3	medicine	P-LAP is available for evaluation of avarian epithelial malignancy and also as target for molecular therapy	668753	
3.4.11.3	medicine	plasma activities of cystinyl-, aspartyl-, and glutamyl-aminopeptidase are decreased by 39.4%, 24.9%, and 33.3%, respectively, in patients with Parkinson's disease	680075	
3.4.11.3	medicine	the enzyme is suggested to be involved in reducing chemosensitivity and may be a therapeutic target in endometrial carcinoma	668752	
3.4.11.3	pharmacology	enzyme IRAP is a therapeutic target for the treatment of limbic seizures	-, 754463